Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Phillip D. Zamore
AddedMar 31, 2024
UpdatedMay 31, 2026
Phillip D. Zamore

Phillip D. Zamore

Board Member, Voyager Therapeutics

CrunchbaseLinkedIn

Phillip D. Zamore's Career

Voyager Therapeutics
Voyager Therapeutics

Cambridge, MA, US

Board Member· Board
Alnylam Pharmaceuticals aln
Alnylam Pharmaceuticals aln

Cambridge, MA, US

Co-Founder
University of Massachusetts Medical School
University of Massachusetts Medical School

Worcester, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Phillip D. Zamore's Career

Voyager Therapeutics
Voyager Therapeutics
Public$374M1252014Cambridge, MA, US
Board Member· Board

Leadership at Voyager Therapeutics

Alfred SandrockAlfred SandrockBoard Member
Steve PaulSteve PaulBoard Member
Michael J HigginsMichael J HigginsBoard Member
Krystof BankiewiczKrystof BankiewiczCo-Founder
Guangping GaoGuangping GaoBoard Member
Mark KayMark KayCo-Founder

Similar to Voyager Therapeutics

Poseida TherapeuticsPoseida TherapeuticsSan Diego, CA, USGene Therapiesest. 2014Poseida TherapeuticsSan Diego, CA, US · est. 2014

San Diego-based Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company innovating cell and gene therapeutics.

Public · $460.5M314
Kriya TherapeuticsKriya TherapeuticsPalo Alto, CA, USGene Therapiesest. 2019Kriya TherapeuticsPalo Alto, CA, US · est. 2019

Kriya Therapeutics: Pioneering gene therapies for global health challenges in ophthalmology, neurology, and metabolism.

Series C · $600.5M194
NeurogeneNeurogeneNew York, NY, USGenetic Medicinesest. 2018NeurogeneNew York, NY, US · est. 2018

Neurogene Inc., a New York-based pharmaceutical company, specializes in developing genetic medicines for rare neurological diseases.

Public · $183.5M92
Intellia TherapeuticsIntellia TherapeuticsCambridge, MA, USGene Editing, Therapiesest. 2014Intellia TherapeuticsCambridge, MA, US · est. 2014

Cambridge-based Intellia Therapeutics pioneers gene editing therapies for genetic diseases.

Public · $1.2B598
Alnylam Pharmaceuticals aln
Alnylam Pharmaceuticals aln
Public$3.9B2k2002Cambridge, MA, US
Co-Founder

Leadership at Alnylam Pharmaceuticals aln

Phillip SharpPhillip SharpBoard Member
Yvonne GreenstreetYvonne GreenstreetCEO
John ClarkeJohn ClarkeBoard Member
Paul SchimmelPaul SchimmelCo-Founder
Amy SchulmanAmy SchulmanBoard Member
Colleen ReitanColleen ReitanBoard Member

Similar to Alnylam Pharmaceuticals aln

Ionis PharmaceuticalsIonis PharmaceuticalsCarlsbad, CA, USPharmaceuticalsest. 1989Ionis PharmaceuticalsCarlsbad, CA, US · est. 1989

Ionis Pharmaceuticals: A US-based biotech firm specializing in RNA-targeted drug discovery for unmet needs.

Public · $1.3B796
Silence TherapeuticsSilence TherapeuticsLondon, Greater London, GBRNA Therapeuticsest. 1994Silence TherapeuticsLondon, Greater London, GB · est. 1994

UK biotech co. discovering molecules with RNA tech to target genes in diseases with unmet needs.

Public · $248.7M120
Atalanta TherapeuticsAtalanta TherapeuticsBoston, MA, USRNA Therapiesest. 2018Atalanta TherapeuticsBoston, MA, US · est. 2018

Atalanta Therapeutics: A biotech pioneer in RNA interference-based treatments for neurodegenerative diseases.

Series A · $110M62
University of Massachusetts Medical School
University of Massachusetts Medical School
GovernmentGovernment$172.9M5.2k1962Worcester, MA, US
Board Member· Board

Leadership at University of Massachusetts Medical School

Celia A SchifferCelia A SchifferBoard Member
Jonathan KayJonathan KayBoard Member
Mary MunsonMary MunsonBoard Member
Frank CarisFrank CarisBoard Member
Jean FrazierJean FrazierBoard Member
Lamar SoutterLamar SoutterFounder

Similar to University of Massachusetts Medical School

University of Massachusetts AmherstUniversity of Massachusetts AmherstAmherst, MA, USEducation, Researchest. 1863University of Massachusetts AmherstAmherst, MA, US · est. 1863

UMass Amherst, a leading public research university in Massachusetts, founded in 1863.

Government · $123.1M11k
University of Missouri School of MedicineUniversity of Missouri School of MedicineColumbia, MO, USMedical Educationest. 1872University of Missouri School of MedicineColumbia, MO, US · est. 1872

University of Missouri School of Medicine, the first public medical school west of the Mississippi.

Government · $16M3k
Johns Hopkins University School of MedicineJohns Hopkins University School of MedicineBaltimore, MD, USMedical Training, Property Leasingest. 1996Johns Hopkins University School of MedicineBaltimore, MD, US · est. 1996

Founded in 1985, Hopkins University specializes in healthcare technology training and property leasing.

Government · $19.9M7.3k
University of Nebraska Medical CenterUniversity of Nebraska Medical CenterOmaha, NE, USMedical Educationest. 1869University of Nebraska Medical CenterOmaha, NE, US · est. 1869

Public academic health science center in Omaha, Nebraska.

Government · $11.8M5k

Phillip D. Zamore's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Phillip D. Zamore

Nathaniel DavidNathaniel DavidBoard Member · Unity BiotechnologyDavid GoeddelDavid GoeddelBoard Member · NGM BiopharmaceuticalsDavid P. BartelDavid P. BartelCo-Founder · Alnylam Pharmaceuticals alnRichard AxelRichard AxelCo-Founder · Kallyope